article thumbnail

Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics

XTalks

Ozempic (Semaglutide) Ozempic sales in 2022: $8.713 billion Company/Developer: Novo Nordisk Date of first FDA approval: December 5, 2017 Indications Ozempic is FDA-approved for: Type 2 diabetes Price of Ozempic: $1,029 for 1.5 Trulicity (Dulaglutide) Trulicity sales in 2022: $7.439 billion Company/Developer: Eli Lilly & Co.

Sales 52
article thumbnail

Diabetes Boosts Odds for Heart Trouble 10-fold in Younger Women

The Pharma Data

21, 2021 – – With rising obesity rates, more young women American women are developing type 2 diabetes , putting them at hugely increased risk for heart disease, new research shows. Insulin resistance occurs when cells in muscles, fat and the liver don’t respond well to insulin and can’t use glucose.

Insulin 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

Delveinsight

Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . It is a complication associated with diabetic patients who take insulin and certain anti-diabetic tablets.

Trials 52
article thumbnail

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

The Pharma Data

“Diabetes is a complex condition, and each specialty should be prioritizing their patients’ overall health and developing treatment plans in collaboration with other specialists without worrying of overstepping,” said Javed Butler, M.D., The findings are from a survey of 1,000 U.S. healthcare professionals (i.e.,

Nurses 52
article thumbnail

FDA grants Jardiance® Breakthrough Therapy designation for heart failure with.

The Pharma Data

Results from EMPEROR-Preserved were presented at the European Society of Cardiology Congress 2021 on August 27 and published in The New England Journal of Medicine. vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. drowsiness.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98
article thumbnail

Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction

The Pharma Data

vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. vice president, Product Development, Lilly. vice president, Product Development, Lilly. The dose of your sulfonylurea or insulin may need to be lowered.

Trials 52